PFE is currently covered by 20 analysts with average potential upside of $9.13 (29.98%) backed by 230 price targets and 279 ratings. Documented since 13-Jul-2012. Analyst's average stock valuation to be materialised ratio is 77.93% with an average time for price targets to be met of 646.33 days.
Most recent stock forecast was given by MOHIT BANSAL from WELLS FARGO on 17-Mar-2023.
Highest price target for PFE is 59, Lowest price target is 34, average price target is 46.5.
Pfizer Inc. is a leading global biopharmaceutical company dedicated to developing, manufacturing and marketing innovative treatments for patients in hundreds of therapeutic areas worldwide. From cardiovascular and women’s health medicines under the Eliquis family and Premarin brands, to small molecules like Ibrance, Xtandi or Retacrit; Immunotherapies such as Lorbrena or Braftovi through anti-infective products including Zavicefta & Medrol.
With a proud history of over 170 years, Pfizer Inc. is established as one of the leading innovators in healthcare and biopharmaceuticals. The company provides groundbreaking biosimilars for chronic immune and inflammatory diseases under key brands such Xeljanz, Enbrel, Inflectra/Eucrisa/Staquis, Cibinqo; along with others focused on amyloidosis, hemophilia and endocrine disorders like Vyndaqel /Vyndamax , BeneFIX & Genotropin . Furthermore they collaborate with other major players including Bristol-Myers Squibb Company; Astellas Pharma US ; Myovant Sciences Ltd.; Akcea Therapeutics etc serving customers like wholesalers retailers hospitals clinics government agencies pharmacies providers offices disease control centers across America.
Pfizer has released oral COVID-19 treatments with a lineup of innovative brand names, including Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid. These medications offer an important alternative for patients that do not respond to conventional treatments and medication types. Each of the Pfizer branded drugs has evidenced positive findings regarding respiratory health indicators in advanced clinical testing results. These medications promise to help restore respiratory distress and decline symptoms in certain groups of COVID-19 patients even amidst inadequate resources or lack of access to traditional medical care.
In the oncology space, Pfizer has established itself as a key player with a number of blockbuster drugs, such as Ibrance, which is used in the treatment of breast cancer, and Xalkori, which is used in the treatment of non-small cell lung cancer. Pfizer also has a strong presence in the immunology space, with products like Xeljanz for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Pfizer’s cardiovascular portfolio includes the blockbuster drug Eliquis, which is used to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation. The company also has a presence in the diabetes space with products like Glucotrol and Glucotrol XL.
Notable programs in the pipeline include abrocitinib for atopic dermatitis, talazoparib for breast cancer, and pneumococcal vaccine candidate PF-06482077. These promising programs are expected to contribute significantly to the company’s future revenue growth. Pfizer’s total revenue for 2021 was $75.7 billion, driven by strong performances from key brands such as Ibrance, Eliquis, Prevnar 13, and Xeljanz.
Pfizer has faced its share of legal challenges over the years. Some of the most notable legal battles the company has faced have been related to its products and business practices.
One of the most high-profile cases involved Pfizer’s painkiller drug Bextra, which was linked to an increased risk of heart attack and stroke. In 2009, the company agreed to pay $2.3 billion to settle allegations that it had improperly marketed Bextra and several other drugs.
Pfizer has also faced numerous lawsuits related to its antidepressant drug Zoloft, with some plaintiffs alleging that the drug caused birth defects in their children. While the company has maintained that Zoloft is safe and effective, it has settled some of these cases out of court.
In recent years, Pfizer has faced lawsuits related to its opioid painkiller drug Embeda, with some plaintiffs alleging that the drug was responsible for addiction and overdose deaths. Pfizer has denied these claims and has been fighting the lawsuits in court
Viagra was one of Pfizer’s most well-known products, and it has played a significant role in the company’s success. Originally developed to treat hypertension and angina, the drug’s side effects led to its more popular use for erectile dysfunction. Launched in 1998, Viagra quickly became a cultural phenomenon and helped make Pfizer a household name. The drug’s success has also been a key driver of Pfizer’s revenue over the years. However, in recent years, Viagra’s sales have declined due to the introduction of generic versions and increased competition from other treatments for erectile dysfunction.
Lipitor is a brand name for the drug atorvastatin, which is a statin medication used to lower cholesterol and reduce the risk of heart disease. It was developed by Pfizer and was first approved by the FDA in 1996. Lipitor became one of the most widely prescribed drugs in the world, with peak sales of over $12 billion annually. It was highly successful for Pfizer and played a major role in the company’s revenue and growth during the late 1990s and early 2000s.
However, the patent for Lipitor expired in the United States in 2011, leading to the availability of generic versions of the drug. This resulted in a significant decline in Lipitor sales, which affected Pfizer’s revenue. Despite the decline in sales, Lipitor remains one of the most successful drugs in the history of the pharmaceutical industry.
Lipitor was also involved in a number of legal disputes. In 2012, Pfizer settled a class-action lawsuit that accused the company of misleading consumers about the safety and efficacy of Lipitor. The lawsuit alleged that Pfizer failed to disclose the risk of diabetes associated with the use of Lipitor. The settlement included a payment of $430 million to consumers who had purchased the drug.
In addition to the class-action lawsuit, Lipitor was also involved in patent litigation. Pfizer filed several lawsuits to protect the patent for Lipitor, which were settled with various generic drug manufacturers. These settlements allowed the generic versions of Lipitor to enter the market in a phased manner, rather than all at once.
Despite the legal issues and the loss of patent protection, Lipitor remains a significant drug in the pharmaceutical industry, and its impact on the treatment of heart disease and cholesterol management has been significant.
The investor sentiment has been positive in recent years. The company has a strong brand reputation, with a long history of developing innovative drugs and vaccines. Additionally, the company’s financial performance has been strong, with solid revenue growth and profitability.
Currently, out of the existing stock ratings of PFE - 64 which are a Hold (71.91%), 25 which are a Buy (28.09%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Hold
48
$8.01 (20.03%)
49
1 months 28 days ago
27/29 (93.1%)
$7.01 (26.65%)
623
1.04
Buy
75
$35.01 (87.55%)
75
1 months 28 days ago
9/13 (69.23%)
$17.92 (49.80%)
850
0.5
Hold
45
$5.01 (12.53%)
53
1 months 28 days ago
10/11 (90.91%)
$4.85 (18.46%)
402
2.3
Hold
44
$4.01 (10.03%)
49
1 months 28 days ago
11/11 (100%)
$2.33 (6.28%)
73
4
What is PFE(Pfizer Inc) average time for price targets to be met?
Which analyst has the current highest performing score on PFE(Pfizer Inc) with a proven track record?
